EN | UA
EN | UA

Help Support

Back

Atogepant is safe and well-tolerated for prophylaxis of episodic migraine

Atogepant Atogepant
Atogepant Atogepant

What's new?

For episodic migraine prophylaxis, long-term use of 60 mg Atogepant once daily-dose is well-tolerated and safe.

A 40-week, open-label extension study showed that 60 mg oral Atogepant once daily-dose has a good safety and tolerability profile when used over the long term for preventive treatment of episodic migraine. Researchers sought to assess the Atogepant's long-term safety and tolerability in subjects who completed the phase 3 ADVANCE study.

Safety was assessed in subjects taking 60 mg Atogepant orally once a day. This was followed by a four-week safety follow-up period. In individuals with episodic migraine, the assessment of tolerability and safety of therapy with oral 60 mg Atogepant tablets, taken once a day for prophylaxis of migraine was the major endpoint ascertained.

Out of 685 subjects who were taking a minimum 1 dosage of Atogepant, 74.6% concluded the treatment period, with a mean (standard deviation) treatment length of 233.6 (89.3) days. Infections of the upper respiratory tract (5.5%), urinary tract infection (5.3%), sinusitis (3.6%), nasopharyngitis (4.8%), constipation (3.4%), and nausea (3.4%) occurring at ≥3% were among the treatment-emergent adverse events that occurred in 62.5% of patients.

There were no fatalities and only 3.4% of patients experienced serious adverse events that were not related to their therapy. Adverse events occurring at >0.1% that were severe enough to cause cessation were migraine, weight loss, vomiting, stomach discomfort, dizziness (0.3% each) and nausea (0.4%). The results were consistent with the drug's established safety profile and supported  long-term usage of 60 mg Atogepant once-daily dosing as well-tolerated and safe.

Source:

Cephalalgia

Article:

Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial

Authors:

Brad C Klein et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: